From the perspective of industrialization, the current development of biopharmaceutical includes two directions: "using genetic engineering processing technology to produce protein" and "using advanced technologies in the field of gene and molecular biology as research tools". The former category of drugs will still be the mainstream of the biotechnology drug market in the next 5-10 years. The latter category of drugs represents the research and development direction of the biotechnology industry, mainly referring to targeted drugs, including therapeutic monoclonal antibodies and therapeutic vaccines. Amgen is the representative of the former type of enterprises, and Genentech is the typical one in the latter type.